Angitia’s Latest Megaround to Fuel Mid-Stage Milestones: Venture Report

Why It Matters

The infusion of capital accelerates Angitia’s progression toward pivotal trial readouts, positioning the company to capture market share in high‑need musculoskeletal therapeutics and enhancing its valuation ahead of potential partnerships or an IPO.

Summary

Angitia Biopharmaceuticals raised a $130 million Series D round, marking its second nine‑digit financing in just over a year after a $120 million Series C and following multiple nine‑figure Series B raises. New investors Frazier Life Sciences and Venrock Healthcare Capital Partners joined existing backers, bringing total recent capital to roughly $250 million. The funding will support Angitia’s three clinical programs—osteoporosis and osteogenesis imperfecta (both in Phase II) and a Phase III spinal fusion candidate—aimed at advancing mid‑stage milestones and de‑risking its pipeline.